CLW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient investor: the primary trend is still bearish (SMA_200 > SMA_20 > SMA_5 + MACD histogram negative and expanding).", "While CLW looks oversold and could bounce near support (S1 ~16.72), there is no Intellectia buy signal today to justify acting immediately.", "Insiders are selling aggressively (+494% vs last month), which weakens the near-term bull case despite a reasonable analyst upside to $21."]
["Trend: Bearish\u2014moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), implying sustained downside pressure.", "Momentum: MACD histogram is -0.27 and negatively expanding, suggesting bearish momentum is strengthening rather than stabilizing.", "RSI: RSI_6 at ~27.27 indicates the stock is near oversold conditions; this can support a short-term bounce, but it is not a confirmed reversal by itself.", "Key levels: Pivot 17.579 (price below pivot at 17.22 = weak). Support at 16.72 then 16.189; resistance at 18.439 then 18.97.", "Pattern-based forward odds: Similar-pattern model implies modest expected moves (next week +1.65% indicated), but not strong enough to override the bearish trend."]
could attract dip buyers.", "Analyst initiation: Truist Hold with $21 PT implies notable upside from ~$17.22 if operations normalize and demand improves.", "Strategic optionality: Management exploration of capacity additions and the \u201cpossible acquisition target\u201d narrative could support valuation if industry dynamics improve.", "Upcoming event: Next earnings (QDec
on 2026-02-12 after hours could act as a catalyst if results/guide improve."]
["Downtrend risk: Bearish MA stack + weakening MACD increases odds of further downside before any durable reversal.", "Insider behavior: Insiders are selling and the selling amount increased ~494% over the last month (negative signal for near-term confidence).", "No supportive news flow: No recent news in the last week to shift sentiment or provide a fresh catalyst.", "Earnings risk: With recent profitability deterioration, the upcoming earnings date can catalyze downside if losses/margins disappoint."]
["Latest quarter: 2025/Q3.", "Revenue: $399M, up ~1.45% YoY (top-line slightly positive but not strong).", "Profitability: Net income -$53.3M (down ~-1018.97% YoY) and EPS -3.3 (down ~-1042.86% YoY) show a sharp deterioration.", "Margins: Gross margin 4.69%, down ~38.69% YoY\u2014core operational pressure is the key fundamental headwind."]
["Recent change: 2026-01-20 Truist initiated coverage at Hold with a $21 price target.", "Wall Street pros: Streamlined portfolio could deliver operating leverage if demand normalizes; lower European imports and possible U.S. supply shifts may help; low leverage and potential M&A interest add optionality.", "Wall Street cons: A Hold rating reflects uncertainty on timing/strength of a recovery; current financial trend (losses and margin compression) makes the turnaround less dependable for near-term buyers.", "Bottom line from analysts: Moderate upside exists to $21, but not enough conviction to call it a clear buy given current operating pressure."]
